- Medicine May 14
On Wednesday, the Centers for Disease Control and Prevention recommended that people most at risk for contracting HIV take a daily pill that has been shown to prevent being infected by the virus.
The CDC's new guidelines state that the drug regimen pre-exposure prophylaxis (PrEP) should be used by gay men who have sex without condoms, anyone who shares needles or injects drugs, heterosexuals with high-risk partners (such as male bisexuals or an intravenous drug user) who have unprotected sex, and people who regularly have sex with partners who are infected, The New York Times reports. The drug Truvada — a mix of tenofovir and emtricitabine that has few side effects and is already used to treat patients in poor countries — costs $13,000 a year and is covered by most health insurers.
"On average, it takes a decade for a scientific breakthrough to be adopted," Dr. Jonathan Mermin, director of the CDC's national center for AIDS and other sexually transmitted diseases, told The Times. "We hope we can shorten that time frame and increase people's survival."
With condom use down among gay men and the HIV infection rate in the U.S. barely changing in a decade, the CDC felt action was necessary. While the regimen should be used along with condoms, many health officials believe people who take Truvada will stop using them. If broadly followed, The Times reports, the drugs will be prescribed to 500,000 people a year, up from fewer than 10,000 now.- - Catherine Garcia
THE WEEK'S AUDIOPHILE PODCASTS: LISTEN SMARTER
- Rise of the machines
- 3 horrific inaccuracies in Homeland's depiction of Islamabad
- Gamergate has backfired spectacularly on its nincompoop perpetrators
- How to be the most productive person in your office — and still get home by 5:30 p.m.
- 43 TV shows to watch in 2014
- It's time to kill school picture day
- 6 things the happiest families all have in common
- The uncomfortable truth in The Giving Tree
- Ban PowerPoint!
- Why you should absolutely watch this confounding, wonderful World Series
Subscribe to the Week